Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 12 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

3 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 2

6(54.5%)

Phase 3

3(27.3%)

Phase 1

2(18.2%)

11Total

Phase 2(6)

Phase 3(3)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials

NCT06122662Phase 2Completed

AMX0035 and Progressive Supranuclear Palsy

Role: lead

NCT05676034Phase 2Active Not Recruiting

AMX0035 in Adult Patients With Wolfram Syndrome

Role: lead

NCT06665165Phase 1Recruiting

AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

Role: lead

NCT06747468Phase 3Active Not Recruiting

Avexitide for Treatment of Post-Bariatric Hypoglycemia

Role: lead

NCT03488524Phase 2Completed

Open Label Extension Study of AMX0035 in Patients With ALS

Role: lead

NCT03533257Phase 2Completed

Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease

Role: lead

NCT05619783Phase 3Completed

Extension Study Evaluating The Safety And Tolerability of AMX0035

Role: lead

NCT05021536Phase 3Active Not Recruiting

Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment

Role: lead

NCT03127514Phase 2Completed

AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Role: lead

NCT04987671Phase 1Unknown

Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS

Role: lead

NCT04516096Phase 2Completed

A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)

Role: lead

NCT05286372Unknown

An Intermediate Size Expanded Access Protocol of AMX0035 for ALS

Role: lead

All 12 trials loaded